focus -WSS

focus

author：leisure time 2025-08-12 09:10:14 - browse：14164

When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say “brash” in French?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.

For more on what we cover, here’s where you can read Frank’s work; here’s more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

focus

knowledge

leisure time

WSS

Lung cancer screening guidelines updated for cigarette smokers

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

What is microchimerism and how does it affect maternal health?

Live blog: Hearing on CRISPR

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

How to convince healthy people to buy insurance

hotspot

focus

hotspot

Heart attack and stroke risk calculators need revising

Humans aren't the only ones with an imagination. Rats have it too

Virginia high school admissions case could be legal follow

All of Us, NIH's precision medicine initiative, gets a big boost

Bright Health sells Medicare Advantage business to Molina

Key Senate panel to consider PBM, drug pricing reform package

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Prime Medicine says its gene editing passes test in monkeys

In age of alternative facts, a scholarly course on calling out crap

After Sarepta trial failure, Duchenne families brace for more debate

leisure time

Inari Medical to buy amputation prevention company LimFlow

The health care issue Democrats can’t solve: hospital reform

Bill would allow buprenorphine prescription for addiction via telehealth

Key Senate panel to consider PBM, drug pricing reform package

Prime Medicine says its gene editing passes test in monkeys

Humans aren't the only ones with an imagination. Rats have it too

focus

knowledge

leisure time

knowledge